Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefepime

T C Hardin1, T S Jennings

  • 1Pharmacy Service, Audie L. Murphy Memorial Veterans Hospital, San Antonio, TX 78284.

Pharmacotherapy
|November 1, 1994
PubMed
Summary
This summary is machine-generated.

Cefepime, a fourth-generation cephalosporin antibiotic, offers broad-spectrum activity against resistant bacteria. Its unique structure enhances bacterial cell penetration and reduces degradation, making it an effective treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The second-look operation improves survival in suboptimally debulked stage III ovarian cancer patients.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2005
Same author

Trends in antifungal research.

EXS·2000
Same author

Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae.

Infection control and hospital epidemiology·2000
Same author

Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.

Clinical therapeutics·2000
Same author

Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans.

Diagnostic microbiology and infectious disease·2000
Same author

Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.

Clinical therapeutics·2000
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Cefepime is a fourth-generation cephalosporin antibiotic.
  • It exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria.
  • It demonstrates enhanced efficacy against bacteria resistant to other cephalosporins.

Purpose of the Study:

  • To review the properties and clinical applications of cefepime.
  • To highlight its advantages over other cephalosporins.
  • To discuss its safety and efficacy in various infections.

Main Methods:

  • Literature review of cefepime's pharmacokinetic and pharmacodynamic properties.
  • Analysis of clinical trial data regarding efficacy and safety.
  • Comparison with other cephalosporin antibiotics.

Related Experiment Videos

Main Results:

  • Cefepime's zwitterionic structure facilitates rapid penetration of Gram-negative bacterial membranes.
  • Low affinity for type I beta-lactamases results in reduced enzymatic degradation.
  • Clinical studies support its effectiveness in treating lower respiratory tract, urinary tract, and skin infections, as well as febrile neutropenia, bacteremia, and septicemia.

Conclusions:

  • Cefepime is a potent antibiotic with a favorable safety profile.
  • It is a valuable therapeutic option for serious bacterial infections, including those caused by resistant pathogens.
  • Its pharmacokinetic and pharmacodynamic properties contribute to its clinical utility.